Curated News
By: NewsRamp Editorial Staff
April 09, 2025
Oragenics Advances Clinical Trial for Concussion Treatment in New Zealand
TLDR
- Oragenics (NYSE American: OGEN) advances clinical trial for ONP-002 neurosteroid therapy, targeting concussion treatment, gaining a competitive edge.
- Oragenics submitted Phase II trial protocol to New Zealand's Health and Disability Ethics Committee, preparing to evaluate intranasal neurosteroid therapy for mild traumatic brain injury.
- Oragenics aims to address the unmet need for concussion treatment, potentially improving patient outcomes and advancing neurology research in Australia and New Zealand.
- Oragenics' innovative approach with ONP-002 neurosteroid therapy for brain injury showcases promising advancements for neurological treatments, sparking interest in medical innovation.
Impact - Why it Matters
This news matters as it highlights Oragenics' progress in developing a potential treatment for mild traumatic brain injury, a condition that affects many individuals globally. The submission of the trial protocol signifies a significant step towards addressing the unmet medical need for effective concussion therapies and could potentially impact the way such injuries are managed in the future.
Summary
Oragenics (NYSE American: OGEN) has submitted its Phase II clinical trial protocol to New Zealand’s Health and Disability Ethics Committee to evaluate its intranasal neurosteroid therapy for mild traumatic brain injury at Christchurch Hospital in Australia. This move aims to address the unmet need for concussion treatment in the region.
Oragenics, a biotechnology company, focuses on nasal drug delivery for neurological and infectious diseases. The company's drug candidates target mild traumatic brain injury and Niemann Pick Disease Type C, along with a proprietary powder formulation and intranasal delivery device.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Oragenics Advances Clinical Trial for Concussion Treatment in New Zealand
